Clinical and Translational Science Award
Clinical and Translational Science Award (CTSA) is a type of U.S. federal grant administered by the National Center for Advancing Translational Sciences, part of the National Institutes of Health. The CTSA program began in October 2006 under the auspices of the National Center for Research Resources with a consortium of 12 academic health centers. The program was fully implemented in 2012, comprising 60 grantee institutions and their partners. Program overview. The CTSA program helps institutions create an integrated academic home for clinical and translational science with the resources to support researchers and research teams working  to apply new knowledge and techniques to patient care. The program is structured to encourage collaborations among researchers from different scientific fields. The CTSA program has raised awareness of clinical and translational science as a discipline among academic and industry researchers, philanthropists, government officials and the broader public. Strategic goals. CTSA consortium leaders have set five broad goals to guide their activities. These include building national clinical and translational research capability, providing training and improving career development of clinical and translational scientists, enhancing consortium-wide collaborations, improving the health of U.S. communities and the nation, and advancing T1 translational research  to move basic laboratory discoveries and knowledge into clinical testing. Selected research areas. Institutions funded by the CTSA program are working with other research facilities to improve drug discovery and development. For example, several consortium institutions are collaborating with the Rat Resource and Research Center at the University of Missouri to increase the speed of drug screening so that drug research is translated into clinical uses more quickly. Consortium institutions also are creating new fields of study or new uses for technologies. For example, researchers at the University of Rochester are pioneering the field of lipidomics, exploring how lipids affect  human disease. Their work has led to lipid research collaborations among experts in community and preventive medicine, proteomics, nutrition, and pharmaceutical research. Some CTSA institutions are collaborating with community-based organizations to ensure research is translated successfully into clinical practice. Researchers at Duke University are working to prevent strokes by partnering with a local health care program to build stroke awareness among Latino immigrants. Others are pursuing public and private partnerships to speed innovation. For example, the Oregon Health and Science University and Intel are developing new wireless devices with sensors to detect symptoms in patients who have diabetes or  those at high risk of stroke so they can be treated earlier. Participating institutions. With the most recent awards, announced in July 2011, the consortium comprises 60 institutions in 30 states and the District of Columbia. These include: Investigations by the Department of Health and Human Services Office of Inspector General (OIG). On the 20 December 2011, the OIG published a report critical of the NIH's administration of the Clinical and Translational Science Awards (CTSA) program. The report read in part: